Here’s our list of reasons as to why we feel OWCP will be the cannabis stock of 2017:
follow OWCP on Twitter https://twitter.com/OWCPharma Market Value: With a low $24 million Market Cap (as of January 1, 2017), they’re have tons of room for growth. We feel they’re so undervalued because they are still pre-revenue. But, that changes in Quarter 2 of 2017.
OTC QB, not Pink Sheets. Most people who are making an investment (not flipping) are usually uncomfortable with Pink Sheet stocks. To see the list of requirements and understand the line of thinking here, check out OTCmarkets.com.
Share Structure: The outstanding share count is 139,255,474 as of January 1, 2017. There’s a couple of cannabis sector stocks trading on the Pink Sheets with 2.3 BILLION outstanding shares No Toxic Debt: Again, unlike many Pink Sheet companies — OWCP has no convertible notes whatsoever. Instead, they have non-interest bearing financing. Distribution & Manufacturing Deals: Back in March 2016, they announced a manufacturing deal with Emilia Cosmetics, one of Israel’s largest private label cosmetics companies. In September 2016, OWCP got a $300,000 deal with MedMar for distribution in the USA. Then, in November 2016, OWCP announced a $300,000 deal with Michepro to promote, market, sell, and distribute products throughout Europe for a 25% cut. Real Doctor(s): Dr. Yehuda Baruch, MD is a real doctor who was the head of the Israeli Medical Use of Cannabis Programme from 2003 – 2012. Read more from the Medical Cannabis Conference website.
Products to Launch: You can see on ClinicalTrails.gov https://clinicaltrials.gov/ct2/show/NCT02976779 that there really is an ongoing study. On October 11th, 2016, they announced the Final Phase for Testing of their Psoriasis Cream. Then, on October 20th, 2016, they announced the completed development of a Medical Cannabis Sublingual Tablet — a smoke-free alternative.
Expert Advisors: OWCP has brilliant industry advisors like Jeffrey Friedland, who wrote the book “Marijuana: The World’s Most Misunderstood Plant“.
Provisional Patents: OWCP has EIGHT provisional patents with the United States Patent and Regulatory Office (USPTO), all related to its line of activity related to cannabis-based medical products.
Acquisition Offer: TEVA, a 115 year old pharmaceutical company with over $20 billion in revenue, made an offer to purchase OWCP’s patents! This leads me to believe there will be future offers as OWCP continues to advance their research and get closer to shipping products worldwide!
Comparison: Simply compare GWPH to OWCP. That’s exactly what OWCP can become later this year. Want to be conservative? If OWCP grows to 1/3rd of GWPH’s Market Value, they’ll be trading around $7.18/share. The reason we feel this is realistic? GWPH has only one FDA approved product thus far. OWCP could easily have two (or more) out by the end of 2017.
We’ll see how things continue to unfold, but there’s no reason not to think big things are going to happen for OWCP in 2017.
News 
Market Data 
Discover 
